350 related articles for article (PubMed ID: 23818496)
21. Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling.
Lindner G; Menrad A; Gherardi E; Merlino G; Welker P; Handjiski B; Roloff B; Paus R
FASEB J; 2000 Feb; 14(2):319-32. PubMed ID: 10657988
[TBL] [Abstract][Full Text] [Related]
22. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways.
Bowers DC; Fan S; Walter KA; Abounader R; Williams JA; Rosen EM; Laterra J
Cancer Res; 2000 Aug; 60(15):4277-83. PubMed ID: 10945642
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.
Gao CF; Xie Q; Zhang YW; Su Y; Zhao P; Cao B; Furge K; Sun J; Rex K; Osgood T; Coxon A; Burgess TL; Vande Woude GF
Mol Cancer Ther; 2009 Oct; 8(10):2803-10. PubMed ID: 19825800
[TBL] [Abstract][Full Text] [Related]
24. Met signaling mutants as tools for developmental studies.
Ponzetto C; Panté G; Prunotto' C; Ieraci A; Maina F
Int J Dev Biol; 2000; 44(6):645-53. PubMed ID: 11061428
[TBL] [Abstract][Full Text] [Related]
25. HGF/SF-met signaling in the control of branching morphogenesis and invasion.
Zhang YW; Vande Woude GF
J Cell Biochem; 2003 Feb; 88(2):408-17. PubMed ID: 12520544
[TBL] [Abstract][Full Text] [Related]
26. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.
Abounader R; Laterra J
Neuro Oncol; 2005 Oct; 7(4):436-51. PubMed ID: 16212809
[TBL] [Abstract][Full Text] [Related]
27. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
28. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma.
Abounader R; Ranganathan S; Kim BY; Nichols C; Laterra J
J Neurochem; 2001 Mar; 76(5):1497-508. PubMed ID: 11238734
[TBL] [Abstract][Full Text] [Related]
29. The biological role of HGF-MET axis in tumor growth and development of metastasis.
Lesko E; Majka M
Front Biosci; 2008 Jan; 13():1271-80. PubMed ID: 17981628
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
31. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.
Otsuka T; Takayama H; Sharp R; Celli G; LaRochelle WJ; Bottaro DP; Ellmore N; Vieira W; Owens JW; Anver M; Merlino G
Cancer Res; 1998 Nov; 58(22):5157-67. PubMed ID: 9823327
[TBL] [Abstract][Full Text] [Related]
32. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes.
Beilmann M; Odenthal M; Jung W; Vande Woude GF; Dienes HP; Schirmacher P
Blood; 1997 Dec; 90(11):4450-8. PubMed ID: 9373255
[TBL] [Abstract][Full Text] [Related]
33. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
[TBL] [Abstract][Full Text] [Related]
34. Targeting MET in cancer: rationale and progress.
Gherardi E; Birchmeier W; Birchmeier C; Vande Woude G
Nat Rev Cancer; 2012 Jan; 12(2):89-103. PubMed ID: 22270953
[TBL] [Abstract][Full Text] [Related]
35. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
36. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach.
Winter A; Sigurdardottir AG; DiCara D; Valenti G; Blundell TL; Gherardi E
Mol Cancer Ther; 2016 Jan; 15(1):3-14. PubMed ID: 26712116
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.
Furge KA; Kiewlich D; Le P; Vo MN; Faure M; Howlett AR; Lipson KE; Vande Woude GF; Webb CP
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10722-7. PubMed ID: 11535809
[TBL] [Abstract][Full Text] [Related]
38. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
Jeffers M; Rong S; Anver M; Vande Woude GF
Oncogene; 1996 Aug; 13(4):853-6. PubMed ID: 8761307
[TBL] [Abstract][Full Text] [Related]
39. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.
Halaban R; Rubin JS; Funasaka Y; Cobb M; Boulton T; Faletto D; Rosen E; Chan A; Yoko K; White W
Oncogene; 1992 Nov; 7(11):2195-206. PubMed ID: 1331934
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
